Dejan Milentijevic | Pharmacoeconomics | United States

Dr. Dejan Milentijevic | Pharmacoeconomics | United States

Janssen Pharmaceuticals | United States

Dr. Dejan Milentijevic is a dynamic and accomplished Health Economics and Outcomes Research (HEOR) Executive with extensive experience in delivering actionable insights and driving strategic decision-making across the pharmaceutical, biotech, and medical device sectors. Renowned for his expertise in oncology, immunology, cardiovascular, and gene therapies, he excels at navigating complex therapeutic landscapes to enhance market access and inform healthcare policy. He skillfully integrates economic modeling, observational studies, real-world evidence, and patient-centered outcomes to optimize payer engagement, guide product launches, and improve patient outcomes. At Johnson & Johnson, he has led transformative initiatives in neuroscience, gene therapy, and cardiovascular portfolios, leveraging cross-functional collaboration, innovative data analytics, and AI-driven approaches to generate evidence supporting lifecycle management and value-based agreements. His prior roles at Celgene Corporation and Market Access Solutions further demonstrate his leadership in real-world evidence generation, budget impact modeling, and strategic market access planning. Dr. Dejan Milentijevic holds a Ph.D. in Biomedical Sciences from Weill Cornell Medical College, an MBA from Rutgers Business School, and advanced technical proficiency in SAS, SPSS, Python, and R statistical programming. With 750 citations, 31 published documents, and an h-index of 12, his research has significantly influenced payer decisions, scientific publications, and healthcare outcomes, underscoring his exceptional impact and ongoing contributions to evidence-based healthcare.

Profile: Scopus | Orcid

Featured Publications

Milentijevic, D., Lin, J. H., Chen, Y.-W., Kogan, E., Shrivastava, S., Sjoeland, E., & Alberts, M. (2021). Healthcare costs before and after stroke in patients with non-valvular atrial fibrillation who initiated treatment with rivaroxaban or warfarin. Journal of Medical Economics.

Khorana, A. A., McCrae, K., Milentijevic, D., McCormick, N., Laliberté, F., Crivera, C., Lefebvre, P., Lejeune, D., Rozjabek, H., Schein, J., et al. (2019). The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation. American Journal of Hematology.

Streiff, M. B., Milentijevic, D., McCrae, K., Yannicelli, D., Lejeune, D., Nelson, W. W., Laliberté, F., Crivera, C., Lefebvre, P., Schein, J., et al. (2018). An answer to “anticoagulant treatment of cancer‐associated venous thromboembolism: Interpreting real‐world data with caution.” American Journal of Hematology.

Streiff, M. B., Milentijevic, D., McCrae, K., Yannicelli, D., Fortier, J., Nelson, W. W., Laliberté, F., Crivera, C., Lefebvre, P., Schein, J., et al. (2018). Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. American Journal of Hematology.

Garland Kgosi More | Pharmacology | Best Researcher Award

Dr. Garland Kgosi More | Pharmacology | Best Researcher Award

Dr. Garland Kgosi More, University of South Africa, South Africa

Dr. Garland Kgosi More is a distinguished agricultural scientist specializing in medicinal plant research, particularly in combating infectious diseases. With a PhD in Agriculture from the University of South Africa (UNISA) and a Master’s in Medicinal Plant Sciences from the University of Pretoria (UP), he has made significant contributions to antiviral, antimicrobial, and phytochemical studies. His groundbreaking research on in vitro anti-Rift Valley Fever Virus and medicinal plant metabolomics has earned him international recognition. Currently, Dr. More serves as a Chief Laboratory Technologist and Senior Lecturer at UNISA, contributing to academic excellence through teaching, supervision, and extensive research. His work is widely published in esteemed journals, and he actively mentors postgraduate students. He is passionate about using indigenous knowledge for modern therapeutic solutions and continues to advance global health through innovative scientific inquiry. 🌿🧬

Publication Profile

scopus

Orcid

Google Scholar

🎓 Education

Dr. Garland Kgosi More earned his Doctor of Philosophy in Agriculture from UNISA in 2021, specializing in in vitro anti-Rift Valley Fever Virus research using 1H-NMR metabolomics. His Master of Science in Medicinal Plant Sciences from UP, awarded with distinction in 2013, focused on the antimicrobial constituents of Artemisia afra against periodontal pathogens. In 2007, he completed his Bachelor of Science Honours in Botany, exploring the antimicrobial properties of medicinal plants targeting oral microorganisms. Prior to this, he obtained a Bachelor of Science in Natural/Biological Sciences from UP in 2006, majoring in Botany and Zoology. Committed to professional development, he pursued certifications in Project Management (2020), Hazardous Chemical Substance Handling (2012), HIV/AIDS Awareness (2009), and Occupational Health and Safety Legislation (2008). His interdisciplinary education has equipped him with a robust foundation in agricultural research, biotechnology, and medicinal plant pharmacology. 🧪🌱

💼 Experience

Dr. Garland Kgosi More has over 15 years of academic and research experience. Currently serving as Chief Laboratory Technologist and Senior Lecturer at UNISA, he provides technical expertise, leads laboratory operations, supervises postgraduate students, and conducts high-impact research. He previously held positions as a Laboratory Technologist at UNISA (2014–2023) and Laboratory Technician at UP (2008–2014). In these roles, he managed high-containment laboratories, implemented safety protocols, and supported undergraduate and postgraduate research. His extensive experience includes research project management, laboratory quality control, and the development of standard operating procedures. He has also contributed to health and safety compliance, waste management, and the application of advanced analytical techniques like NMR and UHPLC-MS. Beyond academia, Dr. More actively engages in community outreach projects, promoting scientific knowledge and empowering emerging researchers. His leadership and dedication have significantly advanced agricultural and medicinal plant research. 🧬📊

🏅 Awards and Honors

Dr. Garland Kgosi More has been recognized for his outstanding contributions to agricultural and medicinal plant sciences. His achievements include publishing in prestigious journals like Scientific Reports, Viruses, and MDPI Antioxidants. His doctoral research on antiviral compounds using NMR metabolomics has earned international acclaim. He has received accolades for mentoring postgraduate students and contributing to their successful research publications. Dr. More has served on academic committees, peer-reviewed journals, and research councils, demonstrating academic leadership. He has also presented at numerous international conferences, sharing insights on medicinal plant pharmacology and disease management. His collaborations with multidisciplinary researchers globally further highlight his dedication to scientific advancement. Committed to public health, he has supported projects addressing infectious diseases like HIV and tuberculosis. Dr. More’s accolades exemplify his unwavering commitment to research excellence and societal impact. 🏆🌿

🔎 Research Focus

Dr. Garland Kgosi More’s research revolves around agricultural biotechnology, phytochemistry, and medicinal plant sciences. His primary focus is the identification and analysis of bioactive compounds from medicinal plants for antiviral, antimicrobial, and anti-inflammatory applications. Using advanced metabolomics, including 1H-NMR and UHPLC-MS, he investigates the therapeutic potential of indigenous South African flora. His studies on antiviral agents against the Rift Valley Fever Virus and antimicrobial properties of Artemisia afra have made significant strides in infectious disease management. Additionally, he explores nanotechnology applications in plant-based drug development and investigates the pharmacological effects of nanoparticles synthesized from plant extracts. His multidisciplinary approach includes in silico modeling, molecular docking studies, and cytotoxicity evaluations. Through his extensive research, Dr. More aims to bridge traditional medicine with modern pharmacology, contributing to the discovery of innovative treatments for viral infections and antimicrobial resistance. 🌿🔬

Publication Top Notes

📚 Antimicrobial activity of medicinal plants against oral microorganismsCited by 242, 2008 🦷🌿
📚 In-vitro analysis of free radical scavenging activities and suppression of LPS-induced ROS production in macrophage cells by Solanum sisymbriifolium extractsCited by 119, 2020 🧪🛡️
📚 Antimicrobial Constituents of Artemisia afra Jacq. ex Willd. against Periodontal PathogensCited by 83, 2012 🌿🦷
📚 Novel silver-platinum bimetallic nanoalloy synthesized from Vernonia mespilifolia extract: Antioxidant, antimicrobial, and cytotoxic activitiesCited by 64, 2020 🧬🦠
📚 Antimicrobial, antioxidant, and cytotoxic properties of biosynthesized copper oxide nanoparticles (CuO-NPs) using Athrixia phylicoides DCCited by 46, 2023 🧪🦠
📚 Alkaloids from aerial parts of Annona senegalensis against Streptococcus mutansCited by 41, 2017 🌿🧬
📚 A review of the ethnopharmacology, phytochemistry and pharmacological relevance of the South African weed Solanum sisymbriifolium Lam. (Solanaceae)Cited by 29, 2019 📖🌱
📚 Synthesis of furocoumarin–stilbene hybrids as potential multifunctional drugs against multiple biochemical targets associated with Alzheimer’s diseaseCited by 23, 2020 🧠💊
📚 Metabolomic profile of medicinal plants with anti-RVFV activityCited by 19, 2022 🦠🧬
📚 Metabolomic Profiling of Antioxidant Compounds in Five Vachellia SpeciesCited by 18, 2021 🌳🛡️
📚 In vitro evaluation of anti-Rift Valley Fever Virus, antioxidant and anti-inflammatory activity of South African medicinal plant extractsCited by 18, 2021 🦠🧪
📚 Lithium inhibits NF-κB nuclear translocation and modulates inflammation profiles in Rift Valley Fever virus-infected Raw 264.7 macrophagesCited by 16, 2021 🧫🛡️
📚 Bio-synthesized calcium carbonate (CaCO3) nanoparticles: Their anti-fungal properties and application as nanofertilizer on Lycopersicon esculentum growth and gas exchangeCited by 14, 2023 🍅🌿
📚 Design, synthesis and evaluation of the 2′-hydroxy-3′-iodo-5′-nitrochalcones for cytotoxicity (MCF-7 & A549) and potential to inhibit tyrosine kinase (VEGFR-2) activityCited by 12, 2024 🧪🧬
📚 Antimicrobial, cytotoxic and oxidative stress inhibitory activities of terpenoids and flavonols from Senegalia nigrescens (Oliv.) PJH HurterCited by 9, 2021 🌿🧫

Conclusion 🏆

Dr. Garland Kgosi More is a highly suitable candidate for the Best Researcher Award. His exceptional academic background, impactful research in antiviral and antimicrobial compounds, significant publication record, commitment to student mentorship, and leadership in scientific research position him as a strong contender for this prestigious recognition.